Pharma back in focus for CLOs after Trump comments
The pharmaceuticals industry is back under the microscope of US CLO players after comments on drug pricing from president-elect Donald Trump hinted at a tougher environment for drug makers under a Trump presidency.
On January 11, the incoming president said that drug companies had “been getting away with murder” with regards to price hiking for too long.Trump's comment sparked a selloff in some US pharmaceutical company stocks and has once again forced CLO investors and issuers to take a hard ...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org